Stock Analiz

GILD vs BIIB stock comparison

Gilead Sciences vs. Biogen · data as of November 13, 2026

Gilead Sciences (GILD) has a market value of about $208.5B, Biogen (BIIB) about $37.5B. Over their latest twelve months Gilead Sciences had revenue of $31.0B and Biogen $10.3B.

On our five checks Gilead Sciences scores higher: 2.8 out of 5 (average) against 1.8 (weak).

By area, the stronger company is Gilead Sciences on track record; Biogen on financial health; Gilead Sciences on shareholder returns.

Gilead Sciences leads on 12 of the compared lines and Biogen on 9.

Side by side

GILDBIIB
Size and price
Market cap$208.5B$37.5B
Share price$168.08$253.40
Score
Overall score (of 5)2.81.8
Value11
Future growth22
Track record41
Financial health34
Shareholder returns41
Valuation
P/E (TTM)—109.2
Forward P/E20.317.4
Price / free cash flow15.118.1
Price / sales6.73.6
EV / EBITDA559.526.7
PEG——
DCF value vs. price−35%−33%
Business
Revenue$31.0B$10.3B
Net income-$3.9B$348M
Free cash flow$13.8B$2.1B
Net margin-12.5%3.4%
Gross margin (5-yr avg.)77.6%76.9%
ROIC (5-yr avg.)12.2%9.2%
Growth
Revenue growth (1 yr)2.4%2.2%
Revenue growth (5 yrs, per year)3.6%-6.0%
EPS growth (5 yrs, per year)132.4%-18.7%
Balance sheet and payouts
Net cash (cash minus debt)-$19.8B-$6.1B
Dividend yield1.95%None
Shareholder yield2.9%0.0%
Analysts
Upside to average target+4%+6%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: GILD TTM to September 30, 2026, BIIB TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Gilead Sciences or Biogen?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Gilead Sciences scores 2.8 out of 5 and Biogen 1.8; the table shows where each one is stronger.

Which grows faster, Gilead Sciences or Biogen?

Over five years Gilead Sciences grew revenue about 3.6% a year and Biogen about -6.0% a year.

Which pays a higher dividend?

Gilead Sciences yields 1.95% and Biogen nothing (no dividend).

Full Gilead Sciences analysis → Full Biogen analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.